S
Sara Arce-Gallego
Researcher at Hebron University
Publications - 4
Citations - 134
Sara Arce-Gallego is an academic researcher from Hebron University. The author has contributed to research in topics: DNA repair & RAD51. The author has an hindex of 3, co-authored 3 publications receiving 37 citations.
Papers
More filters
Journal ArticleDOI
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Antje Neeb,Nicolás Herranz,Sara Arce-Gallego,Susana Miranda,Lorenzo Buroni,Wei Yuan,Alejandro Athie,Teresa Casals,J. Carmichael,J. Carmichael,Daniel Nava Rodrigues,Bora Gurel,Pasquale Rescigno,Pasquale Rescigno,Jan Rekowski,Jon Welti,Ruth Riisnaes,Veronica Gil,Jian Ning,Verena Wagner,Irene Casanova-Salas,Sarai Cordoba,Natalia Castro,Maria de Los Dolores Fenor de la Maza,Maria de Los Dolores Fenor de la Maza,George Seed,Khobe Chandran,Khobe Chandran,Ana Ferreira,Ines Figueiredo,Claudia Bertan,Diletta Bianchini,Diletta Bianchini,Caterina Aversa,Caterina Aversa,Alec Paschalis,Alec Paschalis,Macarena Gonzalez,Rafael Morales-Barrera,Cristina Suarez,Joan Carles,Amanda Swain,Adam Sharp,Adam Sharp,Jesús Gil,Violeta Serra,Christopher J. Lord,Suzanne Carreira,Joaquin Mateo,Johann S. de Bono,Johann S. de Bono +50 more
TL;DR: This data indicates that ATM loss in PC is not always detected by targeted NGS, associates with genomic instability, and is most sensitive to combined ATR and PARP inhibition.
Journal ArticleDOI
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
Suzanne Carreira,Nuria Porta,Sara Arce-Gallego,George Seed,Alba Llop-Guevara,Diletta Bianchini,Diletta Bianchini,Pasquale Rescigno,Pasquale Rescigno,Alec Paschalis,Alec Paschalis,Claudia Bertan,Chloe Baker,Jane Goodall,Susana Miranda,Ruth Riisnaes,Ines Figueiredo,Ana Ferreira,Rita Pereira,Mateus Crespo,Bora Gurel,Daniel Nava Rodrigues,Stephen J. Pettitt,Wei Yuan,Violeta Serra,Jan Rekowski,Christopher J. Lord,Emma Hall,Joaquin Mateo,Joaquin Mateo,Joaquin Mateo,Johann S. de Bono,Johann S. de Bono +32 more
TL;DR: In this article, the authors analyzed TOPARP-B phase II clinical trial samples, evaluating whole-exome and low-pass whole-genome sequencing and IHC and IF assays evaluating ATM and RAD51 foci (testing homologous recombination repair function).
Journal ArticleDOI
Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
Alejandro Athie,Sara Arce-Gallego,Macarena Gonzalez,Rafael Morales-Barrera,Cristina Suarez,Teresa Casals Galobart,Gonzalo Hernandez Viedma,Joan Carles,Joaquin Mateo +8 more
TL;DR: The DNA damage repair pathways are clinically relevant in prostate cancer, being a target for precision medicine; combination with standard-of-care androgen receptor (AR)-targeting agents may be synergistic.
Journal ArticleDOI
Identification of homologous recombination deficiency (HRD) by RAD51 in a tumor molecular profiling program for precision medicine.
Alba Llop-Guevara,Sara Arce-Gallego,Mafalda Melo Oliveira,Sara Simonetti,Cristina Viaplana,Juan Francisco Grau,Carmen García-Durán,Isabel Pimentel,Paola Martinez,José Antonio Jiménez,Rodrigo Dienstmann,Paolo Nuciforo,Joan Carles,Ana Vivancos,Ana Oaknin,Cristina Saura,Susana Aguilar,Joaquin Mateo,Judith Balmaña,Violeta Serra +19 more
TL;DR: The RAD51 test extends the identification of HRD tumors beyond those with HRR gene mutations and captures HRR restoration after PARPi treatment, and complements gene panel sequencing results by providing evidence of functional HRR status.